Gilboa Therapeutics vs ImmunoScape
Gilboa Therapeutics vs ImmunoScape, compared side by side on 13 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Gilboa Therapeutics is on 43/100 and ImmunoScape on 58/100.
Where each one leads
Gilboa Therapeutics
Leads on none of the measures we hold for both companies.
ImmunoScape
- our overall score: 58/100 against 43/100
- agent readiness: 39/100 against 22/100
- domain rating: 28/100 against 4/100
- LinkedIn following: 4,364 against 956
At a glance
| Measure | Gilboa Therapeutics | ImmunoScape |
|---|---|---|
| What it is | Preclinical biopharma developing next-gen cancer immunotherapies using proprietary SolidT technology. | Developing novel immunotherapies and diagnostics for cancer. |
| Category | Biopharmaceuticals, Immunotherapy, Cancer Treatment, Biotechnology | Biotechnology, Cancer, Immunotherapy, Diagnostics |
| Sells toBusiness model | B2G | B2B |
| Offering | Hardware | Platform |
| Founded | 2017 | 2017 |
| Headquarters | Tel Aviv, Israel | Singapore, Singapore |
| Status | Inactive | Active |
Size, funding and growth
| Measure | Gilboa Therapeutics | ImmunoScape |
|---|---|---|
| Employees | 2 | Not published |
| Headcount growthLast 12 months | -49.5% | Not published |
| Total funding | Not published | $49.7M |
| Latest round | Not published | Series B2 |
| Valuation | Not published | $1.1B |
| LinkedIn followers | 956 | 4,364 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | Gilboa Therapeutics | ImmunoScape |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 43/100 | 58/100 |
| Traction | 11/100 | 38/100 |
| Team | Not published | 70/100 |
| Search visibility | 54/100 | 23/100 |
| Quality | Not published | 68/100 |
| Agent readinessHow well an AI agent can read and act on the site | F (22/100) | F (39/100) |
| Domain ratingLink authority, 0-100 | 4/100 | 28/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | Gilboa Therapeutics | ImmunoScape |
|---|---|---|
| CDN | Not detected | Cloudflare |
| CMS | Not detected | WordPress |
| Frameworks | Not detected | Jquery |
| Analytics | Not detected | Google Tag Manager |
What users say
| Measure | Gilboa Therapeutics | ImmunoScape |
|---|---|---|
| Reddit sentimentThreads we track | Not published | 6 positive, 0 negative across 6 threads |
“Singapore-based ImmunoScape Pioneers Next-Generation Cell Therapy for Solid Tumors; Announces Key Licensing Deal, New Board and SAB Appointments.”r/Quantisnow
Gilboa Therapeutics vs ImmunoScape: common questions
Which is better, Gilboa Therapeutics or ImmunoScape?
On our 0-100 score ImmunoScape rates higher (58/100 against 43/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 13 data points above: read the rows that match what you are buying for.
How do Gilboa Therapeutics and ImmunoScape compare on the numbers?
ImmunoScape leads on our overall score (58/100 against 43/100), agent readiness (39/100 against 22/100), domain rating (28/100 against 4/100), LinkedIn following (4,364 against 956).
What do real users say about Gilboa Therapeutics and ImmunoScape?
ImmunoScape: 6 positive and 0 negative mentions across 6 Reddit threads we track, mostly in r/Quantisnow.
Read the full Gilboa Therapeutics review and pricing or the ImmunoScape review and pricing. You can also browse other Gilboa Therapeutics alternatives we track.